News
Slideshow
Trump’s ‘most-favored nation’ drug price push: Key takeaways from our expert panel
Trump’s “most favored nation” drug pricing order could lower costs but raise new challenges for physicians, patients and pharma.
Physicians and every sector of the health care system are watching closely as President Donald Trump’s 2025 executive order on “most favored nation” (MFN) drug pricing raises new questions about the future of pharmaceutical costs in the United States.
To help unpack the potential impacts, MJH Life Sciences® brands, including Medical Economics, hosted a live webinar on Sept. 10, bringing together a panel of experts with perspectives from economics, investment, law and the payer sector.
The slides below include panelist bios and 5 key takeaways from the panel discussion.
Click here to register for free and watch the full panel, on demand.
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.
